After 4 years with blood donation mobilization and blood component production, we obtain encouraging results, as following: 1. Renovation on blood donor source, from 90% of professional donor in 1993, down to 53% in 1997. 2. Blood collection volume is increased 3 times in 1997 in comparison to the collection in 1993. 3. Blood transfusion is ensured to be safer than in the past, by systemic application of screening test of HBV, HCV and HIV. Through screening, we detected thousands peoples with positive HBsAg, hundreds of positive anti HCV and anti HIV. These take an important part to ensure blood transfusion safety. 4. It is separated into 4 basic blood components, with packed red cell, platelet concentrated, frozen fresh plasma and cryoprecipitate. 5. It takes about 70% of partial blood transfusion among total blood transfused in 1997, compared to less than 10% before year’s 1994. Obviously, blood donation mobilization takes benefit not only for treatment service, but also for blood transfusion safety and people health care with high economic value.
Blood Donors ; Metabolism ; Blood

During 5 years period(1994-1998) blood donor motivation and blood component preparation, encouraging results have been achieved: 1. Renew of blood resources with 90% of donors was professional in 1993 changed to 53% and 37% in 1997 and 1998, respectively. 2. Blood collection volume per year raised 4 times in comparing with the data in 1993 (800 litres to 2,850 litres in 1998). 3. 1,000 of donors with HBsAg(+) and 100 of donors with anti-HCV(+) and anti-HIV(-) have been excluded by screening. 4. 4 basic blood component have been prepared including red cell concentrates, platelet concentrates, fresh frozen plasma and anti haemophilia A cryoprecipitates. 5. 70% of clinical transfusion carried out with blood components and blood transfusion reaction have been decreasing. 6. Obviously, blood donor motivation gave a lot of advantage to patient treatment, blood transfusion safety, health care system with better economic effectiveness.
Blood Donors ; metabolism ; Blood

The incidence of mother to new born transmission of HBV at birth and breath nursing period is very high, about 45% and 40% respectively. The mother who are also positive HBeAg are in highest risk to transmit HBV to newborn. All HBV makers, seen in mother serum, could be found out from cord blood. The new born with positive HBsAg are in high risk to be chronic carrier for HBV. These data show that, it is very essential to detect HBsAg from mother and then indicate early vaccination to newborn whose mother is positive HBsAg. This has benefit not only to people health care but protection to safe blood donor in the future.
Blood Donors ; Transmission ; Mothers ; Newborn ; HB-VAX

In Vietnam we have been screening 5 blood transmitted diseases: HBV, HCV, HIV, malaria and syphilis. In order to get safe blood for patients since 1994 we have concentrated in 3 issues: voluntary blood donation program, screening blood transmitted diseases in all hospitals (from central to district hospitals-85 central and provincial hospitals and 430 district hospitals), production of safe blood components and effective clinical blood use. The result: in 1999 all blood banks in Vietnam perform screening HIV for 100% blood products; in 2001 all hospital use 100% blood products screened for HBV, HCV, HIV. More than 840 donors with anti-HIV(+) were excluded. Until now only 1 case of HIV in the window period. This result has been reported so far due to the blood collection in the window period. This result also shows the effectiveness of the prevention program for HIV/AIDS in blood transfusion practice.
Blood Donors ; Transmission ; HB-VAX ; HIV

Using WHO questionnaire on blood safety HIV/AIDS prevention indicator survey (data collection protocol), it was revised and added by NIHBT, we get the results on the knowledge of clinical doctors in 6 surveying hospital. The records-keeping system was not uniform. The knowledge of clinical doctors on blood transfusion practice was ready yet. The results will be using to develop interventions to achieve this outcome in future.
blood transfusion ; Knowledge ; hospitals

The 7th April 2000 is the date of global health. Because the increase of HIV/AIDS as well as hepatitis B, hepatitis C... were threatening the blood transfusion safety, the director general of WHO introduced the date of global health was considered the date of blood transfusion safety with the slogan "blood safety begins me, the blood save the life".
Blood Transfusion ; Safety

The world health organization (WHO) considered the World health day as day of blood transfusion safety with slogan blood safety begins, blood cures the life to mobilize everyone over the world takes care the blood program through the humane blood donation and assurance of blood safety. WHO called for each country must have blood program under direct management of Ministry of health. The answer to this call, the institute of hematology and blood transfusion mobilize “blood safety year” organized in 11/03/2000.
Blood transfusion ; Safety

There were 39 aplastic anemia patients with immunopathology, who was treated by immunosuppresion such as: Spleenectomy, thymus transplantation using cyclosporine A. The results show that: immunosuppression has successful rate of 50-60% in aplastic anemia after internal treatment was not effectiveness.
Bone Marrow Diseases ; Immunosuppression ; Therapeutics

There are 21 pro-myeloid leukemia patients were treated by ATRA from 4/1999 to 12/2000 with dose 40 mg/day in 90 days. The results should that: there are 62% remission after 40.8 days, 5% was good in 15 months, 33% was death, among 71.4% the cause of death by the brain bleeding. The disorder coagulation was good after 15 days of treatment. The count of red cell, white cell, platelet become normal after 45 days. The result shows that the early diagnosis was necessary for preventing disorder coagulation by using high dose corticoid. It was addition of FFP and cryoprecipitate
Leukemia ; therapeutics

From 1996 to 2000, 609 patients of acute leukemia in NIHBT, Bach Mai hospital were applied immunophenotype. The results as follow: Acute myeloid leukemia (AML): 408 patients (67%) including: AML (CD14-): 367patients (60.3%), AML (CD14+): 41patients (6.7%). Acute lymphoid leukemia (ALL): 123 patients (20.2%) including: PreT: 16 patients (2.6%), T: 3 patients (0.5%), Early B: 2 patients (0.3), PreB: 81 patients (13.3%), 21 patients (3.45%), 78 patients (only CD34+). NK acute leukemia: 1 patient (CD16/56+), Acute “null-cell” leukemia: 17 (all CDs negative on blasts), Mixed acute leute leukemia myoloid-B: 16 patients (CD13+, CD33+ and /or CD3; CD7+), Mixed acute leukemia myeloid-NK: 7 patients (CD13+, CD33+ and/or CD16/56+). These results contributed effectively to pathological study, folow up treatment and prognosis of acute leukemia
Leukemia ; immunology ; diagnosis